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Introduction
Members of the TGF-β superfamily play significant roles in
development, cell differentiation and tissue morphogenesis in
embryos and adult organisms (Massague, 1990; Taipale et al.,
1998). The prototypic members of the family, the TGF-βs, are
secreted from cells as biologically latent complexes. The dimeric
TGF-β molecule associates noncovalently with its processed
dimeric N-terminal propeptide, also called latency-associated
protein (LAP) (Fig. 1A). For TGF-β to bind to its signaling
receptors and exert its biological functions, the cytokine must be
released from the small latent complex (SLC) by a process
referred to as activation (Annes et al., 2003). LAP also binds
covalently to the latent TGF-β binding protein (LTBP-1, -3 or
-4) (Miyazono et al., 1988). The binding of the SLC to LTBP
produces the large latent complex (LLC) (Fig. 1A), and it is in
this form that TGF-β is secreted from most cell types.
LTBPs are 120-220 kDa glycoproteins composed of multiple
epidermal growth factor (EGF)-like repeats and four domains
containing eight cysteines – the 8-Cys or cysteine rich (CR)
domains (Fig. 1A). EGF-like repeats provide stability to
protein structures via calcium binding and participate in
noncovalent protein-protein interactions (Davis, 1990). The
CR domains are unique to the fibrillin/LTBP superfamily and
their function(s) are not well understood. The third CR
domains of LTBP-1, -3 and -4 bind LAP (Gleizes et al., 1996;
Lack et al., 2003; Saharinen et al., 1996b; Saharinen et al.,
1998; Yin et al., 1995), whereas the other CR and hybrid
domains may be involved in matrix binding (Unsold et al.,
2001). LTBPs are important for the folding, secretion and
targeting of TGF-β to the ECM (Miyazono et al., 1991; Taipale
et al., 1994). Indeed, null and hypomorphic mutations of the
Ltbp-3 and Ltbp-4 genes have yielded phenotypes associated
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Transforming growth factor-β is released from most cells
as an inactive complex consisting of transforming growth
factor-β, the transforming growth factor-β propeptide and
the latent transforming growth factor-β-binding protein.
We studied the role of latent transforming growth factor-
β-binding protein in modulating transforming growth
factor-β availability by generating transgenic mice that
express a truncated form of latent transforming growth
factor-β-binding protein-1 that binds to transforming
growth factor-β but is missing the known N- and C-
terminal matrix-binding sequences. As transforming
growth factor-β is an inhibitor of keratinocyte proliferation
and is involved in the control of hair cycling, we over-
expressed the mutated form of latent transforming growth
factor-β-binding protein under the control of the keratin
14-promoter. Transgenic animals displayed a hair
phenotype due to a reduction in keratinocyte proliferation,
an abbreviated growth phase and an early initiation of the
involution (catagen) phase of the hair cycle. This phenotype
appears to result from excess active transforming growth
factor-β, as enhanced numbers of pSmad2/3-positive nuclei
are observed in transgenic animal skin. These data suggest
that the truncated form of latent transforming growth
factor-β-binding protein-1 competes with wild-type latent
transforming growth factor-β-binding protein for binding
to latent transforming growth factor-β, resulting in latent
transforming growth factor-β complexes that fail to be
targeted correctly in the extracellular matrix. The mis-
localization of the transforming growth factor-β results in
inappropriate activation and premature initiation of
catagen, thereby illustrating the significance of latent
transforming growth factor-β-binding protein interaction
with transforming growth factor-β in the targeting and
activation of latent transforming growth factor-β in
addition to previously reported effects on small latent
complex secretion.
Supplementary material available online at
http://jcs.biologists.org/cgi/content/full/118/10/2177/DC1
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with decreased SLC secretion (Dabovic et al., 2002a; Dabovic
et al., 2002b; Sterner-Kock et al., 2002). At least three distinct
regions of LTBP-1 associate with the ECM. The first (hybrid),
the second and the region around fourth CR repeats of LTBP-
1 interact with the ECM (Nunes et al., 1997; Olofsson et al.,
1995; Saharinen et al., 1996a; Taipale et al., 1994; Unsold et
al., 2001). The model proposed by Unsold et al. (Unsold et al.,
2001) suggests that the initial interactions of LTBP-1 with the
ECM involves the N-terminal regions of LTBP-1 followed by
interaction of the C-terminal region. The N- and C-terminal
regions can bind independently to the ECM, and each has the
ability to inhibit the association of exogenous LTBP-1 with
fibroblast ECM (Unsold et al., 2001). The strong N-terminal
binding sites may anchor the protein, and the weaker C-
terminal site may subsequently stabilize the binding. LTBP-1
colocalizes with fibronectin (Taipale et al., 1996), elastin
(Karonen et al., 1997) and fibrillin-1 (Dallas et al., 2000; Isogai
et al., 2003; Raghunath et al., 1998; Sakai et al., 1986).
A significant fraction of the latent cytokine is covalently
associated with the ECM (Miyazono et al., 1991; Miyazono et
al., 1992; Taipale et al., 1992; Taipale et al., 1995). Liberation
of active TGF-β from its ECM-bound form requires several
steps (Annes et al., 2003; Koli et al., 2001). In the case of
protease-mediated activation, the first step may involve the
release of the latent complex from the ECM by proteolytic
cleavage of LTBP-1 at protease-sensitive sites (Koli et al.,
2001; Taipale et al., 1992; Taipale et al., 1995). The second
step, activation of latent TGF-β, liberates TGF-β from its
noncovalent complex with LAP. This process is mediated by
interaction with proteases, integrins or thrombospondin in cell-
type-specific ways (Annes et al., 2003; Koli et al., 2001). As
TGF-β regulates the expression of ECM components and the
extracellular proteolytic balance, TGF-β activation is a key
element in a complex and finely controlled feedback system of
ECM remodeling (Koli et al., 2001). 
The action of TGF-β has been extensively examined in the
skin. Several transgenic mouse models have been generated
in which TGF-β and TGF-β receptor function have been
perturbed in the epidermis using keratin- or keratinocyte-
specific gene promoters to express different forms of the
cytokine or its receptor. These models have produced
significantly different epidermal phenotypes depending on the
specific mode, place and time of expression of different TGF-
β isoforms and their receptor, as well as different activation
mechanisms (Blessing et al., 1995; Blessing et al., 1996; Cui
et al., 1995; Fowlis et al., 1996; Ito et al., 2001; Sellheyer et
al., 1993; Wang et al., 1997; Wang et al., 1999). However, they
all support the conclusion that TGF-β influences proliferation
and apoptosis in the epidermis and regulates ECM synthesis in
the dermis (Frank et al., 1996; Shah et al., 1999; Streuli et al.,
1993). Moreover, TGF-β has been proposed to regulate the
apoptosis-driven onset of catagen during hair cycling (Kim et
al., 1998; Lindner et al., 1997; Maurer et al., 1997; Weedon
and Strutton, 1981). The hair follicle proceeds cyclically
through three phases of growth: hair shaft formation (anagen),
hair shaft involution (catagen) and quiescence (telogen). The
first phase of hair follicle development is called postnatal hair
follicle morphogenesis. Studies with TGF-β1 null mice further
support the hypothesis that TGF-β1 plays an important role in
catagen induction (Foitzik et al., 2000; Philpott et al., 1994;
Soma et al., 1998). Consistent with this possibility, TGF-β and
TGF-β receptor type II expression is maximal at the anagen-
catagen transition (Paus et al., 1997; Welker et al., 1997).
To examine the role of LTBP-1in latent TGF-β1 activation,
we generated transgenic mice that ectopically express the TGF-
β-binding EGF-CR3-EGF region of LTBP-l (ECR3E, the third
CR repeat flanked by two EGF-like repeats) under the control
of the keratin 14 (K14) promoter (Wang et al., 1997) (Fig. 1D).
We reasoned that ECR3E would exert a dominant negative
effect by competing with endogenous LTBP for covalent
association with latent TGF-β1, and there would be no
inhibition of SLC secretion, as in the Ltbp knockout and
hypomorphic mutants (Dabovic et al., 2002a; Dabovic et al.,
2002b; Sterner-Kock et al., 2002). Our approach would permit
us to distinguish between LTBP effects on latent TGF-β after
secretion verses the effect of the earlier reported mutations that
impair secretion. As ECR3E lacks the LTBP-1 sequences
required for ECM incorporation, latent TGF-β bound to
ECR3E will fail to bind to the matrix (Nunes et al., 1997;
Taipale et al., 1994; Unsold et al., 2001). Thus, the majority of
the latent TGF-β will remain as a soluble latent complex and
its activation may be altered (Annes et al., 2004).
The K14-ECR3E transgenic mice displayed decreased
keratinocyte proliferation, an abbreviated anagen, early
induction of catagen and shorter hair. These phenotypes
correlate with the presence of higher levels of active TGF-β1
in the transgenic skin as measured by increased amounts of
nuclear pSmad2/3 in keratinocytes. These data suggest that
LTBP-1-facilitated targeting of latent TGF-β1 into the ECM
plays an important role in modulating latent TGF-β1
activation. In addition, constructs of the type described offer
the potential to modulate TGF-β availability in a novel manner
in other tissues.
Materials and Methods
Reagents
Agarose, protein-A agarose, Lipofectamine Plus, optimem and
DMEM were purchased from Gibco Laboratories (Grand Island, NY).
Bouin’s solution, eosin, hematoxylin and permount were purchased
from Sigma Chemical Co. (Springfield, NJ). Proteinase K and salmon
sperm were purchased from Roche Applied Science (Indianapolis,
IN). Mouse anti-HA IgG was purchased from BabCo (Richmond,
CA). ECL and HRP-conjugated goat anti-mouse IgG were purchased
from Amersham Pharmacia Biotech (Piscataway, NJ). Endonucleases
were purchased from Boehringer Mannheim Corp. (Indianapolis, IN)
and New England Biolabs (Beverly, MA). [α-32P] dCTP was
purchased from Perkin Elmer NEN Life Science Products, Inc.
(Boston, MA). G418 sulfate was purchased from Meditech (Herndon,
VA). Rabbit polyclonal anti-Myc IgG (A14) and anti-pSMAD2/3 (SC-
11769) were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). VB3A9, a mouse anti-LAP IgG was produced in our laboratory
(Nunes et al., 1998). Normal mouse IgG was purchased from Sigma
Chemical Co. Ab39 was a gift from K. Miyazono (Tokyo University),
LAP was prepared in our laboratory and anti-TGF-β neutralizing
antibody was purchased from R&D Systems (Minneapolis, MN).
BrdU was purchased from Sigma. BrdU was revealed using the
Boehringer biotinylated anti-BrdU antibody.
Cell culture
B9-293 (a gift from B. Arrick, Dartmouth Medical School, Hanover,
NH) is a stable cell line that expresses high levels of SLC (Arrick et
al., 1992). These cells were cultured in DMEM (Gibco Laboratories)
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supplemented with 10% fetal bovine serum (FBS) and penicillin-
streptomycin-glutamine (PSQ) at 37°C with 5% CO2. HT1080 cells
(American Type Culture Collection, Rockville, MD) were cultured in
DMEM supplemented with 10% FBS and PSQ at 37°C with 5% CO2.
Primary murine keratinocytes were isolated from newborn (1-3 day
old) ECR3E-Myc transgenic and wild-type littermates as described
previously (Glick et al., 1994). Cells were cultured in low calcium (50
µM CaCl2) 5-MEM (Life Technologies) containing 8% FBS treated
with chelex resin, 100 µg/ml penicillin G and 100 µg/ml streptomycin
sulfate.
Mammalian cell expression of ECR3E-Myc and ECR3E1-2-
Myc
pcDNA3–ECR3E-Myc or –ECR3E-1-2-Myc were transiently
transfected into B9-293 cells using Lipofectamine Plus according to
the manufacturer’s instructions. Cells were grown for 48 hours and
incubated in serum-free media (Optimem) for 24 hours. The proteins
in the conditioned media were separated by 7% SDS-PAGE under
reducing conditions, transferred to a nitrocellulose membrane, and
western blotted using rabbit anti-Myc IgG and HRP-conjugated anti-
rabbit antibody. To detect the formation of the complex between either
ECR3E-Myc or ECR3E-1-2-Myc and TGF-β, the samples were
separated by 7% PAGE under nonreducing conditions and blotted
with either VB3A9 or mouse anti-Myc IgG (A14). The signal was
detected by ECL and exposed to Kodak X-OMAT film.
To show that ECR3E-Myc protein competes with LTBP-1 and
binds latent TGF-β, HT1080 cells were transfected with either
pcDNA3-ECR3E-Myc or pcDNA3-ECR3E-1-2-Myc constructs using
Lipofectamine Plus and selected with G418 (500 µg/ml) for 1 week.
Several cell clones were isolated and maintained in DMEM
supplemented with G418 (250 µg/ml), 10% FBS and PSQ. The cells
were incubated with Optimem for 2 days, and the conditioned media
collected for western blot analysis. The conditioned media were
resolved by 7% SDS-PAGE under nonreducing conditions, transferred
to a nitrocellulose membrane and immunoblotted with specific
antibodies. The immunoblots were performed with anti-Myc antibody
to detect the ECR3E-Myc protein, Ab 39 to detect both the free and
complexed (to LAP) LTBP-1, and VB3A9 to detect LAP, ECR3E-
Myc-LAP complex and LTBP-1-LAP complex. The signal was
detected by ECL with Kodak X-OMAT film.
K14-ECR3C-Myc and K14-ECR3E-1-2-Myc transgenic
constructs
Myc-tagged ECR3E (a region spanning EGF-like domain 13, CR3
and EGF domain 14 of LTBP-1 (Fig. 1C) was amplified from
pcDNA3-LTBP-1S by PCR using the primers 5′-CACTAGTGGATG-
TGAATGAATGTGAATGCTC-3′ and 5′-GCTCTAGAGTCACGT-
GAGATCCTCCTCAGAAATCAGCTTTTGCTCGGTTAACTCCAG-
GTCACTGTCTTTCTC-3′ with restriction sites for directional
cloning. The (SpeI-XbaI) ECR3E-Myc fragment was subcloned into
pRcCMV plasmid containing the BM 40 signal peptide (a gift from
R. Timpl, Martinsried, Germany) and sequenced. Subsequently a
HindIII-XbaI ECR3E-Myc fragment was transferred into pBluescript
for mutation/deletion procedures. To convert the LTBP-1 ECR3E into
LTBP-2 ECR3E (ECR3E-1-2), the pBlueECR3E-Myc plasmid was
subjected to mutation/deletion procedures using Quick-Change Site
directed Mutagenesis Kit (Stratagene) and the following primers:
5′-GATAACTGCgacctcTGCCCGGTCTTGGGAACTGC-3′ and 5′-
GCAGTTCCCAAGACCGGGCAgaggtcGCAGTTATC-3′. The lower
case letters represent the sequences where the mutations were
introduced. In this construct, the codons for the amino acids E
(glutamic acid, residue 48) and I (isoleucine, residue 49) of LTBP-1
CR3 were mutated to resemble the LTBP-2 codons for the amino acids
D (aspartic acid) and L (leucine) (Fig. 1B). The glutamic acid and
isoleucine residues correspond to amino acids 1058 and 1059 in
LTBP-1S sequence (Lack et al., 2003). At the same time, the FP
(phenylalanyl proline) amino acid sequence of LTBP-1 CR3 was
deleted with the same primers (Fig. 1B). For expression analyses in
mammalian cells, the HindIII-XbaI fragment was cloned into
pcDNA3 plasmid.
The ECR3E-Myc and ECR3E-1-2-Myc cDNAs were excised from
pcDNA3-ECR3E/ECR3E-1-2-Myc by HindIII and BamHI digestion,
blunted by Klenow, and subcloned between the K14 promoter and a
3′ noncoding region of the human growth hormone (hGH) gene,
which contains an intron and a polyadenylation signal in the K14-
hGH cassette (a gift from Elaine Fuchs, Rockefeller University, NY)
(Wang et al., 1997). Plasmid DNA was prepared using a Qiagen
(Valencia, CA) purification kit. The K14-ECR3E-Myc-hGH and K14-
ECR3E-1-2-Myc-hGH transgenes were excised from the pGEM 3Z
backbone with KpnI, and HindIII. The 5.5 kB transgenes were gel
purified by electroelution, and re-suspended in the injection buffer (5
mM Tris-HCl pH 8.0, 0.1 mM EDTA). The DNA was forwarded to
the Transgenic Mouse and Microinjection Facility at the Skirball
Institute (N.Y.U. School of Medicine) for injection into the pronuclei
of fertilized FVB/N oocytes of female mice.
Genotyping ECR3E-Myc and ECR3E1-2-Myc transgenic mice
Genomic DNA was prepared by digesting 1 cm of mouse tail in 1
mg/ml of proteinase K in 50 mM Tris-HCl (pH 8.0), 100 mM NaCl,
50 mM EDTA, 1% SDS for 6-16 hours at 55°C with shaking, followed
by isopropanol and 70% ethanol precipitations. Genotyping of the
ECR3E-Myc and ECR3E-1-2-Myc transgenic mice was performed
with PCR, using primers 5′-CGTTTTCACAGAAGGCTTCACC-3′
(anneals to the EGF-like domain 13) and 5′-CTGTGGGTGATGAA-
AGCCAAG-3′ (anneals to the end of the K14 promoter sequence).
For Southern blot analysis, genomic DNA samples (10-20 µg) were
digested with 80 units of BamHI (ECR3E-Myc mice) or SacI
(ECR3E-1-2-Myc mice) and separated by electrophoresis in 1X TAE
– 0.8% Agarose gel at 3 V/cm. The treatment of the gel, transfer to
Hybond-XL nylon membrane and hybridization was performed
according to the manufacturer’s protocol (Amersham Pharmacia
Biotech, UK) using [α-32P]-labeled probe, specific activity 3000
Ci/mmol. As a probe, we used the BamHI-SacI fragment (500 bp)
corresponding to the upstream region of the hGH in the K14-pGEM
32 constructs. Blots were washed twice in 2X SSC, 0.1% SDS, for 15
and 30 minutes at 65°C, once in 0.5% SSC, 0.1% SDS for 10 minutes
at 65°C, and exposed to Kodak X-OMAT film at 80°C for 1-3 days.
Co-immuno precipitation and TGF-β activity assays
For immunoprecipitation of the LLC and/or Myc-tagged transgenes,
either anti-LTBP-1 (Ab39) or anti-Myc (A14), were used. Wild-type
and transgenic primary keratinocytes were isolated (Glick et al., 1994)
and plated at a density of 7106 cells/well on 6-well plates in low
Ca++ medium. After 3 days, conditioned media were collected and
pre-cleared by adding 200 µl/ml of Protein A Agarose (50% in PBS)
and incubating for 45 minutes at 4°C. The cleared supernatants were
immunoprecipitated in the presence of an anti-Myc antibody (5
µg/ml), nonspecific rabbit IgG (5 µg/ml), and anti-LTBP-1 IgG
(2 µl/ml) or pre-immune rabbit serum (2 µl/ml). After 2 hours at 4°C,
50 µl samples of Protein A Agarose (50% on PBS) were added and
the incubation continued for an additional 45 minutes at 4°C.
Immunoprecipitates were washed three times with 1 ml of washing
buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1% Triton X100) and
once with 1 ml of PBS. Each sample was re-suspended in DMEM
containing 0.1% BSA and heat activated at 80°C for 10 minutes. The
TGF-β activity in immunoprecipitates was determined by the mink
lung epithelial cell luciferase assay after heat activation of latent
complexes (Abe et al., 1994; Mazzieri et al., 2000). Briefly, 2.5104
cells were plated per well in 96-well plates and incubated 3-4 hours
at 37°C. At that time, media containing the samples from
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immunoprecipitation were added to the cultures. Specificity of the
signal was determined by incubation of the samples with either LAP,
which inhibits TGF-β activity, or specific anti-TGF-β neutralizing
antibodies. After 16-20 hours, the cells were washed with PBS, lysed,
and the luciferase measured. The results are presented as % of samples
incubated in the absence of LAP or anti-TGF-β.
Measurement of hair length in ECR3E-Myc and ECR3E-1-2-
Myc transgenic mice
For measurement of hair length, the pelage hairs were plucked from
the back of the neck of ECR3E-Myc, ECR3E-1-2-Myc transgenic and
wild-type littermates at various time intervals during the first 21 days
of life. The samples were obtained at various stages of the hair cycle,
including the neofollicular growth stage, the catagen or regression
stage, and the telogen or resting stage (Wilson et al., 1994). Hairs were
evaluated using Alpha Imager 2000 Documentation and Analysis
System (Alpha Innotech Corporation, San Leandro, CA), which
projects a magnified image of the plucked hairs onto a computer
screen. Plucked hairs were viewed on the screen and separated by
tweezers to identify the various subtypes of hair (guard/monotrich,
awl and zigzag). Hair length was measured on the computer screen
by dragging the cursor across the image of the hair. For each
transgenic or wild-type mouse examined, a range of 10 to 15 of the
guard/monotrich hairs and 20 to 30 each of the awl and zigzag hairs
were measured.
Histology of ECR3E-Myc and ECR3E-1-2-Myc transgenic
mouse skin
Full thickness mouse skin biopsies were taken from the middle of the
back from ECR3E-Myc, ECR3E-1-2-Myc transgenic and wild-type
littermates at various time intervals during the first 21 days of life.
Biopsy specimens were fixed in 4% paraformaldehyde in PBS for 16
hours at 4°C, processed in gradients of alcohol and embedded in
paraffin. Sections, 4-5 µm, were cut and attached to poly-Lysine
coated SuperPlus slides (Fisher Scientific, Springfield, NJ). The
sections were deparaffinized in xylene, rehydrated, and stained with
hematoxylin and eosin.
BrdU incorporation
Transgenic and wild-type newborn littermates were injected
intraperitoneally with 0.2 mg of BrdU per g body weight 1 hour before
killing. Skin was dissected from middorsum, fixed in 70% ethanol for
16 hours at 4°C, and paraffin embedded. 4 µm skin sections were
incubated 20 min at room temperature in 0.3% H2O2, washed three
times 3 minutes each in dH2O, denatured for 15 minutes at 37°C in 1.5
N HCl, washed in dH2O as before, and blocked for 20 minutes at room
temperature in PBS and 10% FCS. Cells incorporating BrdU into the
DNA were localized by incubating sections for 1 hour at room
temperature with a biotinylated anti-BrdU antibody diluted 1:10 in
PBS/10% FBS, followed by three washes with PBS for 5 minutes each,
and a final incubation with horseradish peroxidase-conjugated
streptavidin. Sections were counterstained with hematoxylin. The
labeling index was determined by counting BrdU-positive cells per total
interfollicular basal cells in ten randomly selected fields per animal.
Detection of Myc and pSmadD2/3 in sections of skin from
transgenic mice
Frozen or paraffin sections of skin samples were subjected to
immunohistological staining for detection of the Myc antigen and
pSmad2/3 using either rabbit anti-Myc or anti-pSmad2/3 antibodies.
For detection of Myc, skin biopsies were fixed in 4%
paraformaldehyde, frozen in OCT compound and the sections
immediately fixed in Bouin’s solution for 5 minutes at RT and washed
once in 70% ethanol and twice in PBS (10 minutes each). The slides
were blocked in 2% goat serum and incubated overnight with the anti-
Myc antibody at 1:100 dilution. After washing, the signal was
revealed using the Fast-red system (BioGenex, CA), counterstained,
and pictures were taken using a Zeiss light microscope. The detection
of pSmad2/3 was performed as follows. Briefly, deparaffinized
sections were treated with DAKO®Target Retrieval Solution in a
Black & Decker steamer according to the manufacturer’s protocol
(DAKO Corporation, CA). After blocking with PBS/2% goat serum
for 1 hour at room temperature, the samples were incubated with
1:200 dilutions of the pSmad2/3 antibody and nonimmune IgG (as
background control) overnight at 4°C. After washing in PBS, the
samples were incubated for 1 hour at room temperature with biotin
labeled secondary anti-rabbit antibody. The detection of the signal and
counterstaining of the nuclei was performed by incubation of the
samples with streptavidin Alexa Fluor® conjugate (1 µg/ml)
(Molecular Probes, OR) and DAPI (50 ng/ml) (Roche Applied
Science, IN) in PBS for 30 minutes at room temperature. After a brief
wash, the slides were mounted in Fluoromount-G (Southern
Biotechnology Associates, AL) and viewed using a Zeiss fluorescence
microscope. Pictures were taken at random using a Hammamtsu
digital camera and Openlab 2.2.5 software. The blue DAPI stained
nuclei were artificially colored in green using Openlab software so
that the overlapping signals with the red stain for pSmad gave a better
contrast (yellow-orange). At each time point, four random fields from
each of two slides for each genotype were counted. The results are
represented as percentage pSmad-positive cells (yellow-orange
signal) of the total cell (green plus yellow-orange nuclei) number.
Results
LTBP-1 has been shown to target latent TGF-β1 to the ECM
(Miyazono et al., 1991; Nunes et al., 1997; Taipale et al., 1994;
Unsold et al., 2001). To elucidate the significance of the
interaction of LLC with ECM on TGF-β activation and
signaling, we generated two constructs that coded for truncated
forms of LTBP-1: ECR3E-Myc and ECR3E-1-2-Myc (Fig.
1C). The first LTBP-1 construct (ECR3E-Myc) contains the
LAP-binding third CR domain flanked by EGF-like domains,
but lacks the regions that mediate LTBP-1 association with the
ECM (Gleizes et al., 1996; Saharinen et al., 1996b; Unsold
et al., 2001). Thus, ECR3E-Myc should compete with the
endogenous LTBP-1 for binding to SLC and prevent targeting
of SLC to the ECM. The second LTBP-1 construct (ECR3E-
1-2-Myc) encompasses the same LTBP region but with two
amino acids mutated and two others deleted, thereby altering
the sequence to resemble the LTBP-2 CR3 domain (Fig. 1B),
which cannot covalently associate with LAP (Saharinen et al.,
1998). Thus, the protein encoded by ECR3E-1-2-Myc cannot
compete with the native LTBP-1 for binding to SLC and serves
as a negative control for the binding of SLC to ECR3E-Myc.
To verify that both constructs functioned as proposed,
HT1080 cells were stably transfected with either pcDNA-
ECR3E-Myc or pcDNA-ECR3E1-2-Myc and the conditioned
media from these cultures analyzed using western blotting with
anti-Myc, anti-LAP or anti-LTBP antibodies. As shown in Fig.
2A, both ECR3E-Myc and ECR3E-1-2-Myc were well
expressed, but only ECR3E-Myc blocked the association of
LAP with the endogenous LTBP-1 (Fig. 2B). Furthermore, the
expression of ECR3E-Myc but not that of ECR3E-1-2-Myc
resulted in the formation of a slowly migrating complex that
contains LAP (Fig. 2C). Similar results were obtained using
B9-293 cells (data not shown). These results indicate that
ECR3E-Myc and ECR3E-1-2-Myc are expressed, secreted and
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behave as predicted with regard to their ability to associate and
compete with native LTBP for binding to LAP.
Transgenic mice
To determine the effects of in vivo overexpression of ECR3E-
Myc and ECR3E-1-2-Myc on TGF-β activation, transgenic
mice were produced in which the two deletion mutants of
LTBP-1 were expressed under the control of the K14-promoter
(Fig. 1C) specific for expression in basal keratinocytes and the
outer root sheath (ORS) of the hair follicle (Wang et al., 1997).
Basal keratinocytes are known targets of TGF-β and their
proliferation is inhibited by TGF-β (Frank et al., 1996; Shah
et al., 1999; Streuli et al., 1993). In addition, previous
immunohistochemical analyses suggested that the cells
primarily affected by TGF-β in the hair follicle during the hair
cycle are localized in the ORS during late anagen (follicle
morphogenesis) and catagen (Isogai et al., 2003; Paus et al.,
1997; Seiberg et al., 1995; Soma et al., 2003; Welker et al.,
1997).
ECR3E-Myc mice
Six mice were positive for the K14-ECR3E-Myc transgene
both by Southern analysis of tail DNA. (Southern analysis of
tail DNA from ECR3E-Myc and ECR3E-1-2-Myc mice as well
as PCR analysis for genotyping is illustrated in Fig. S1 in
supplementary material.) Five founders showed transmission
of the transgene to the Fl generation. Two of these founders
were used to establish two independent lines because of the
strong skin phenotype shown by their transgenic progeny.
There was no loss of ECR3E-Myc embryos based on the
Mendelian pattern of transgene transmission in adult animals. 
ECR3E-1-2-Myc mice
Six founder mice were positive for the K14-ECR3E-1-2-Myc
transgene by both Southern and PCR analysis of tail DNA.
However, only four founders transmitted the transgene to their
progeny. Two founders were used to establish two
lines. As in the case of ECR3E-Myc mice, there
was no embryonic lethality of ECR3E-1-2-Myc
mice. 
Association of ECR3E-Myc with SLC
To verify the ability of ECR3E to associate with the
SLC produced by murine keratinocytes, co-
immunoprecipitation of conditioned media from
wild-type and transgenic cells was combined with
a TGF-β activity assay (Fig. 3). Basal keratinocytes
were isolated from ECR3E-Myc transgenic and
wild-type newborn littermates. When grown in low-
Ca2+ medium, cultures of primary keratinocytes
show a basal cell phenotype (Glick et al., 1994; Li
et al., 1995). An anti-Myc antibody was used to
immunoprecipitate ECR3E-Myc from transgenic
and wild-type keratinocyte-conditioned medium,
and an anti-LTBP antibody was used to
immonoprecipitate LLC from wild-type
keratinocyte-conditioned medium. The co-
Fig. 1. LTBP-1, ECR3E-Myc, ECR3E-1-2-Myc and transgene
constructs. (A) LTBP-1 structure and its binding to LAP and TGF-
β through the CR3 region. Ovals represent CR domains, rectangles
EGF-like domains; LAP is in black, and mature TGF-β in orange.
(B) The amino acid sequence of the CR3 region of the LTBP-1
(ECR3E-Myc) and the mutations introduced to convert ECR3E-
Myc into CR3 that resembles that of LTBP-2 (ECR3E-1-2), which
does not bind TGF-β. The amino acid changes are boxed and the
deleted amino acids are labeled with arrows. (C) Transgene
products. The two CR3 regions (oval) surrounded by the EGF-like
repeats (rectangles) tagged with Myc tag (long rectangle) that were
used in making the transgene constructs represented in D. (D) K14
transgene constructs. The keratin 14 (K14) promoter was used to
drive the expression of ECR3E-Myc constructs into the basal layer
of the epidermis. The human growth hormone 3′ untranslated
region and poly A (hGH poly A) were added for stabilization of the
transcript. Primers used for PCR are represented by arrows and the
fragment of the hGH used for Southern blotting indicated by the
bold lines.
Fig. 2. Expression of the ECR3E-Myc and ECR3E-1-2-Myc proteins and
competition with endogenous LTBP for binding to the small latent complex
(SLC) in transfected cells. Western blot analyses of conditioned media of
ECR3E-Myc, ECR3E-1-2-Myc or mock transfected HT1080 cells. (A) Reducing
conditions and anti-Myc antibody. (B) Nonreducing conditions and anti-LTBP
antibody. (C) Nonreducing conditions and anti-LAP antibody.
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immunoprecipitation of TGF-β was verified using the PAI-1-
luciferase TGF-β assay (Abe et al., 1994; Mazzieri et al., 2000).
The results of this experiment (Fig. 3) indicate that anti-
LTBP antibody co-immunoprecipitates TGF-β from wild-type
cell conditioned medium, showing that cultured epidermal
keratinocytes produce and secrete the LLC. The fact that the
response of the assay is TGF-β-specific is shown by the
inhibition of the response by LAP. TGF-β activity is blocked
by anti-TGF-β1 neutralizing antibodies, not by anti-TGF-β3
antibodies, and only slightly by anti-TGF-β2 antibodies
identifying TGF-β1 as the major LTBP-associated TGF-β
isoform produced by cultured basal keratinocytes. The TGF-β
isoform profile of cells in vivo may be different than
what is observed in vitro. The anti-Myc antibody co-
immunoprecipitates TGF-β from transgenic ECR3E-Myc cell
conditioned medium indicating that ECR3E-Myc associates
with SLC produced by transgenic basal keratinocytes.
Again, TGF-β activity was almost completely blocked by anti-
TGF-β1 neutralizing antibodies or LAP, whereas nonimmune
rabbit serum or IgG immunoprecipitated essentially no TGF-β
activity. Taken together, these data show that overexpressed
ECR3E-Myc associates with latent TGF-β1 and therefore
competes with native LTBP for the binding to LAP in basal
keratinocytes derived from ECR3E-Myc transgenic mice.
Phenotype
The in vivo presence of the K14-ECR3E-Myc and K14-ECR3E-
1-2-Myc transgenes was examined by immunohistochemical
staining of back skin from 9-day-old wild-type and transgenic
littermates using an anti-Myc antibody as described in Materials
and Methods. The Myc tag was detected primarily in basal
keratinocytes and ORS sheath cells of hair follicles in both
ECR3E-Myc and ECR3E-1-2-Myc transgenic mice but not in
wild-type littermates (Fig. 4A). RT-PCR experiments revealed
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Fig. 3. Co-immunoprecipitation of
ECR3E and TGF-β activity from
primary keratinocytes. Wild-type and
transgenic (ECR3E) primary
keratinocytes were isolated and
grown in low calcium medium.
Conditioned medium was collected
and used in immunoprecipitation (IP)
experiments with either anti-Myc
(A14) or anti-LTBP (Ab39)
antibodies. Nonimmune rabbit-IgG
(RIgG) or rabbit serum (RS) were
used as negative controls.
Immunoprecipitates were analyzed
for TGF-β activity using the PAI-1-
luciferase assay as described in
Materials and Methods. PAI-1-
luciferase transfected mink lung cells were grown for 16 hours in the presence of heat-activated wild-type (wt) or transgenic (tg)
immunoprecipitates in the absence or in the presence of LAP or neutralizing isoform-specific anti-TGF-β antibodies (anti-TGF-β1, anti-TGF-
β2 and anti-TGF-β3).
Fig. 4. Expression of the transgenes in vivo. (A) The Myc-tagged
transgenes were detected using anti-Myc antibody in sections of
back skin from 9-day-old mice. Both ECR3E-Myc and ECR3E-1-
2-Myc transgenic animals showed labeling in the basal layer of the
epidermis and the outer root sheet (ORS) of the hair follicle.
Control (WT) littermates did not show significant labeling of these
regions. (B) Expression of the TGF-β1 and LTBP-1 visualized
using RNA extracted from isolated epidermis or cultured
keratinocytes followed by RT-PCR. (C) Wild-type and transgenic
(ECR3E-Myc) mice at day 11.
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expression of TGF-β1 and LTBP-1 in both ECR3E
transgenic and wild-type epidermis and cultured basal
keratinocytes (Fig. 4B).
Short hair
Mice from all transgenic ECR3E-Myc lines, but not
normal littermates (Fig. 4C) or ECR3E-1-2-Myc mice
(not shown), displayed a slight change in color due to
the visibility of the skin through the hair. Examination
of these animals revealed that their hair was shorter than
that of normal littermates. The difference in hair growth
was grossly visible in animals by day 12 after birth,
became more evident between days 15 and 40, and
diminished in older mice presumably because hair
growth is synchronized during the first two cycles but
not thereafter. To further analyze the hair phenotype,
back hairs were plucked from ECR3E-Myc and
ECR3E-1-2-Myc transgenic and normal littermates at
different ages and examined for morphology and length.
No difference in the percentage of each of three major
types of hair (guard, awl and zigzag) was observed
between transgenic and normal littermates. However, all
hair types from the ECR3E-Myc transgenic mice
displayed a progressive reduction in length compared
with wild-type hair during the first hair cycle. A
maximum difference of 30% was reached 15 days after
birth (see Fig. S2A in supplementary material). The
control ECR3E-1-2-Myc mice showed no reduction in
hair length when compared with wild-type littermates
(see Fig. S2B in supplementary material). 
Early induction of catagen
The hair follicle proceeds cyclically through three
phases of growth: hair shaft formation (anagen), hair
shaft involution (catagen) and quiescence (telogen).
The length of the hair shaft depends primarily on the
number of days that a follicle remains in anagen (Stenn
and Paus, 2001). This fact and the proposed
involvement of TGF-β in the onset of catagen (Foitzik
et al., 2000; Paus et al., 1997; Philpott et al., 1994;
Seiberg et al., 1995; Soma et al., 2003; Soma et al.,
1998; Welker et al., 1997) suggested that the duration
of anagen might be modified in the ECR3E-Myc mice
due to altered levels of active TGF-β. This hypothesis
was evaluated by histological examination of the
follicular morphogenesis in transgenic and wild-type
mice during the first hair cycle. No apparent
histological differences were observed between the
transgenic and normal skin of newborn mice (Fig. 5).
However, a striking difference was observed in the hair
follicles of ECR3E-Myc mice compared with wild-type
skin starting from day 6 and especially around day 15
(Fig. 5). Normal murine hair follicles finish postnatal
follicle morphogenesis and enter catagen at day 18 post
partum (p.p.) (Stenn and Paus, 2001). However, at day
15 p.p., when the wild-type follicles were still in the
late follicle morphogenesis phase, ECR3E-Myc transgenic
follicles had already entered the catagen phase (Fig. 5), as
shown by the fact that the hair bulbs no longer surrounded the
dermal papillae, which were left behind by the regressing
follicles (Fig. 5, day 15). At day 18 p.p. transgenic follicles had
begun the resting telogen phase, whereas wild-type hair
Fig. 5. Histological analyses of the hair cycle. Skin sections from mice
stained with hematoxylin and eosin were analyzed at days 0-21. (A) Wild-
type (WT) tissues at day 15 displayed hair morphology typical of the late
postnatal hair follicle morphogenesis phase, with well-differentiated hair
follicles characterized by large oval hair bulbs surrounding the dermal
papillae (arrow). At the same day after birth, the ECR3E-Myc transgenic
follicles had already entered the catagen phase as evidenced by the regressing
follicles with the papilla outside of the hair bulb (arrow). (B) The control
ECR3E-1-2-Myc skin had a hair cycle similar to that of the wild-type skin as
illustrated by the fact that the hair was in late postnatal hair follicle
morphogenesis phase at day 15 and was not distinguishable from wild-type
follicles of the same age. 
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follicles did not begin telogen until day 21 p.p. (Fig. 5). These
changes in hair cycle were also apparent in the first hair cycle
(data not shown) and appeared to persist throughout the life of
the animals – transgenic ECR3E-Myc mice always had shorter
hair even when the hair cycles were no longer synchronized.
In addition, skin thickness increased during the anagen phase
as the developing follicles elongated into the fat layer.
However, skin from ECR3E-Myc mice was thinner than wild-
type skin. The difference in skin thickness between wild-type
and ECR3E-Myc mice was not due to a difference in the
thickness of the epidermis or dermis, but to the adipose layer,
which remains thin in the transgenic skin. The control ECR3E-
1-2-Myc mice displayed the same skin thickness, follicle
morphology and catagen onset as the wild-type mice (Fig. 5),
indicating that the phenotypes observed in the ECR3E-Myc
mice were due to the association of ECR3E with the
endogenous SLC and not to the expression of the transgene
product by itself.
Because the main factor in determining hair length is the
duration of the growth phase, we conclude that the short hair
phenotype observed in ECR3E-Myc mice is mostly due to the
reduction of the postnatal follicle morphogenesis phase,
resulting from the early onset of catagen. As TGF-β is believed
to be involved in the induction of catagen (Foitzik et al., 2000),
the early onset of catagen in the ECR3E-Myc transgenic mice
suggests that latent TGF-β1 activation and consequently TGF-
β1 activity are enhanced in the presence of ECR3E-Myc
LTBP-1 mutants. 
Inhibition of keratinocyte proliferation
Because TGF-β1 is a potent inhibitor of epithelial cell
proliferation both in vitro (Coffey et al., 1988; Shipley et al.,
1986; Wilke et al., 1988) and in vivo (Foitzik et al., 2000;
Sellheyer et al., 1993; Wang et al., 1997), we determined the
rate of proliferation in the epidermis of transgenic and normal
newborn littermates from two ECR3E-Myc transgenic lines
(44 and 60). Mice were injected with BrdU 1 hour before they
were killed, and back skin sections were analyzed for BrdU
incorporation as described in Materials and Methods. Both
ECR3E-Myc transgenic lines showed a reduction in the
proliferation of interfollicular basal keratinocytes of 54.4% and
43.2%, respectively. These results are in agreement with an
enhanced TGF-β1 activity in the presence of ECR3E-Myc
LTBP-1 mutants.
Detection of phosphorylated Smad2/3
Our attempts to directly measure active TGF-β in whole tissue
using antibody or fluorescence approaches were unsuccessful.
Therefore, we indirectly measured TGF-β signaling by
immunohistochemical staining for phosphorylated Smad2
and Smad3 (pSmad2/3) on mouse skin from wild-type and
transgenic animals at days 0, 2, 6, 9, 12, 15, 18, 21, 23 and 26
throughout the first hair cycle as described in Materials and
Methods. Phosphorylation of Smad2/3 is a consequence of
TGF-β signaling and the pSmads are translocated to the
nucleus where they regulate transcription (Derynck and Zhang,
2003; Kawabata et al., 1998; Shi and Massague, 2003;
Stroschein et al., 1999). Thus, nuclear localization of
pSmad2/3 is a reflection of TGF-β signaling. When skin
samples were stained for pSmad2/3 (red), as well as DAPI
(green) for nuclei, cells in which pSmad2/3 was present in the
nucleus appeared yellow-orange (Fig. 6A). Positive nuclei
were counted only in the hair follicles not in the interfollicular
regions and the percentage of pSmad positive nuclei for the
three mouse types were plotted as a function of day after birth
(Fig. 6B). (Although the illustration shows only the upper
dermis, the sections used for counting included all regions of
the epidermis and dermis.)
The percent of pSmad2/3-positive nuclei in the wild-type
follicles was 25% at birth and went through three peaks during
the first hair cycle (Fig. 6B). There was a slight rise in the
percentage of positive nuclei at day 2, a second larger increase
between days 9 and 12, and a third increase between days 18
and 21. Following the third peak, there was a significant
decrease in the number of pSmad-positive nuclei back to the
level observed at day 0. Skin from animals expressing the
control ECR3E-1-2-Myc displayed a pattern of pSmad-positive
nuclei in the follicles equivalent to that observed with the wild-
type skin, indicating that the overexpression of the non-TGF-β-
binding protein had no effect on TGF-β signaling. However,
at the initial sampling time, day 0, ECR3E-Myc follicles
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Fig. 6. Detection of phosphorylated Smad2/3 (pSmad2/3) in the skin
of wild-type and transgenic animals during the first hair cycle.
(A) Immunocytochemistry using pSmad2/3 antibody and Alexafluor
visualization of activated Smad2/3 on sections from 9-day-old mice.
The positive pSmad2/3 signal stained red. The DAPI-stained nuclei,
which were blue, were artificially colored green. Therefore, cells
with pSmad2/3 in the nucleus appeared yellow-orange because of the
red green overlap. Green arrows indicate pSmad-negative nuclear
staining, yellow arrows indicate pSmad-positive nuclear staining.
(B) The number of pSmad-positive cells in hair follicles is
represented as a percentage of the total number of cells in at least
eight fields from each sample of skin from animals 0 to 26 days after
birth. The follicles in the skin of ECR3E-Myc animals have higher
levels of positive cells compared with the follicles of the wild-type
and ECR3E-1-2-Myc. 
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contained considerably more pSmad2/3-positive nuclei
than controls (40% vs. 25%). The level of TGF-β
signaling remained higher than the control values at all
times except at days 12 and 21, at which time the wild-
type and ECR3E-1-2 follicles showed peak values of
pSmadd2/3-positive nuclei. The ECR3E-Myc follicles
showed peaks of enhanced numbers of positive nuclei in
the follicles at day 9. This peak may correspond to the
peak observed in the control skin at day 12. A slight
increase in the number of pSmad-positive nuclei was
also observed in the follicles of ECR3E-Myc skin at day
21, and this was followed by a decline of positive nuclei
back to the level observed at day 0. Higher numbers of
pSmad-positive cells at day 0 correlate with the BrdU
incorporation data and the reduction in keratinocyte
proliferation observed in ECR3E-Myc mice. Moreover,
the premature high level of TGF-β signaling, as indicated
by increased numbers of pSmad-positive cells, at day 9
instead of day 12, correlates with the inhibition of hair
growth and the early induction of catagen in the ECR3E-
Myc mice.
Discussion
The purpose of the present study was to elucidate the
possible function of LTBP-1 in targeting TGF-β to the
ECM and the effect of modifying TGF-β ECM
interactions on the regulation of latent TGF-β activation.
The ECR3E region of LTBP-1, where covalent binding
to TGF-β LAP occurs, was expressed under the control
of the K14 promoter in the basal cells of the epidermis
and ORS of the hair follicle. Basal keratinocytes were
chosen as target cells because of the known effects of
TGF-β1 on keratinocyte biology. However, the transgene
product should bind all three TGF-β isoforms. Both
epidermal and follicular keratinocytes express TGF-β1,
TGF-β receptors and LTBP-1 in a very site- and time-
specific manner during the hair cycle (Paus et al., 1997;
Tumbar et al., 2004; Welker et al., 1997). Mouse skin,
therefore, provides a particularly informative in vivo
animal model system to study TGF-β biology.
Several reports have shown that TGF-β inhibits
keratinocyte proliferation and induces keratinocyte
apoptosis – events important for both epidermal homeostasis
and hair follicle regression during the anagen-catagen
transition (reviewed by Massague, 1990; Sakai et al., 1986;
Sporn and Roberts, 1990). Overexpression of constitutively
active TGF-β in mouse skin results in mice with taut, stretched
skin with suppressed proliferation of epidermal and follicular
keratinocytes (Sellheyer et al., 1993). By contrast,
overexpression of dominant-negative TGF-β receptor type II in
mouse skin causes a 2.5-fold increase in the BrdU labeling
index in the epidermis and results in mice with wrinkled skin
(Wang et al., 1997). In addition, TGF-β1-deficient mice have
a significantly prolonged anagen phase compared with their
wild-type or heterozygous littermates, and the local injection
of active TGF-β1 reverts the phenotype (Foitzik et al., 2000).
We concentrated our attention on the postnatal hair follicle
development because it is de novo and because morphogenesis
is synchronized. During this period, the TGF-βRII, which
binds active TGF-β and forms heterodimers with the TGF-βRI,
is specifically expressed in the epidermal keratinocytes that
will form the hair placode and in all keratinocytes of the
developing outer root sheath (ORS) in the invaginating and
differentiating hair follicles (Paus et al., 1997).
As a consequence of ECR3E expression, we obtained mice
with reduced epidermal keratinocyte proliferation, shorter hair,
shortened morphogenesis and early onset of growth arrest. All
phenotypes correlated with increased numbers of Smad2/3
positive nuclei, a marker of active TGF-β, in the follicles of
ECR3E-Myc skin compared with wild-type skin. Transgenic
mice overexpressing a mutant form of ECR3E-Myc that is
unable to bind latent TGF-β did not display short hair,
shortened postnatal hair follicle morphogenesis or increased
nuclear pSmad2/3. Therefore, the observed phenotypes are the
result of the overexpression of a mutated form of LTBP-1
capable of binding latent TGF-β. Quantitative differences in
the skin of wild-type and transgenic animals were observed in
the length of the hair and the degree of pSmad2/3 signaling.
Fig. 7. Model for latent TGF-β activation in ECR3E-Myc and ECR3E-1-2-
Myc skin. (A) In the presence of wild-type LTBP and/or ECR3E-1-2-Myc, the
latent TGF-β SLC is bound to LTBP and sequestered into the matrix. This
prevents latent TGF-β from interacting with cell-associated activators until the
appropriate time. (B) In the situation in which ECR3E-Myc is overproduced,
it out-competes LTBP for binding to SLC. The complex of ECR3E-Myc and
SLC is not incorporated into the ECM as it is missing the N- and C-terminal
matrix binding sites of LTBP. The soluble latent TGF-β complex, therefore,
interacts with cell-associated activators generating active TGF-β, which
causes increased signaling through its receptor and accumulation of nuclear
pSmad2/3.
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Unfortunately, because the ECR3E protein can bind TGF-β1,
TGF-β2 or TGF-β3, we cannot define which TGF-β isoform
is altered in our system. We propose that ECR3E binding to
LAP prevents LTBP-1-dependent latent TGF-β deposition into
the ECM, which, in turn generates unbound ‘soluble’ latent
TGF-β (Fig. 7). In this model, an increased soluble pool of
latent TGF-β bound to ECR3E causes the inappropriate
presentation of the latent TGF-β to activators localized on the
cell surface (Annes et al., 2003) and release of active TGF-β.
Support for this supposition derives from the work of Neptune
and colleagues (Neptune et al., 2003), who showed that in the
absence of fibrillin-1, an ECM binding partner for LTBP-1, an
excess of active TGF-β1 is produced in the lungs. Thus, latent
TGF-β that is not sequestered in the ECM may be
inappropriately activated. The mechanism for this activation is
unknown but could involve any one of the known pathways for
latent TGF-β activation (Annes et al., 2003).
Previous reports describing the phenotypes of Ltbp null or
hypomorphic mutations concluded that the observed
phenotypes were the result of a TGF-β deficit, as in the absence
of Ltbp the SLC secretion is inhibited (Dabovic et al., 2002a;
Sterner-Kock et al., 2002). The results of the experiments
presented in this paper are not related to decreased secretion of
TGF-β, as latent TGF-β levels were normal. The inappropriate
TGF-β signaling we observed strongly implies a function for
LTBP modulation of latent TGF-β action after secretion in
addition to the previously observed deficits on SLC release.
ECM-associated latent TGF-β may represent a storage form,
which allows for a rapid, highly localized TGF-β response,
potentially bypassing the need for new protein synthesis (Annes
et al., 2003). LTBP-mediated matrix incorporation regulates the
soluble pool of latent TGF-β and prevents inappropriate
activation of latent TGF-β. The inability to direct latent TGF-β
into the matrix facilitates the inappropriate activation of the
latent cytokine, resulting in heightened signaling. Thus, the
deposition of TGF-β in the ECM, an event facilitated by LTBPs,
is important in the regulation and fine-tuning of signaling events
that are dependent on TGF-β. In addition, perturbation of LLC
interaction with the ECM utilizing mutated LTBPs may yield
insights into TGF-β functions.
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